The convergence of aPaaS (Application Platform as a Service) with COTS (Commercial Off-The-Shelf) solutions and low-code development is reshaping how pharmaceutical companies build and deploy applications for quality, manufacturing, and laboratory operations.
Traditional approaches to pharmaceutical software — either building custom solutions or implementing rigid COTS packages — each have significant limitations. Custom development is expensive and slow, while COTS solutions often require extensive customization to fit specific business processes.
aPaaS with low-code capabilities offers a middle path that combines the speed of COTS deployment with the flexibility of custom development. Pre-validated components for common pharmaceutical workflows (deviation management, change control, CAPA) can be configured and extended using visual tools rather than traditional coding.
The benefits for pharmaceutical companies include 10x faster deployment, 70% lower total cost of ownership, built-in regulatory compliance features, and the ability to rapidly adapt applications to changing business requirements and regulatory expectations.